BR1100080A - Compostos derivados de indol e composição farmacêutica - Google Patents

Compostos derivados de indol e composição farmacêutica

Info

Publication number
BR1100080A
BR1100080A BR1100080-5A BR1100080A BR1100080A BR 1100080 A BR1100080 A BR 1100080A BR 1100080 A BR1100080 A BR 1100080A BR 1100080 A BR1100080 A BR 1100080A
Authority
BR
Brazil
Prior art keywords
aryl
alkyl
hydrogen
nr5r6
compounds
Prior art date
Application number
BR1100080-5A
Other languages
English (en)
Inventor
John E Macor
Martin James Wythes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR1100080(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Priority to BR1100080-5A priority Critical patent/BR1100080A/pt
Publication of BR1100080A publication Critical patent/BR1100080A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR1100080-5A 1990-10-15 1996-11-12 Compostos derivados de indol e composição farmacêutica BR1100080A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR1100080-5A BR1100080A (pt) 1990-10-15 1996-11-12 Compostos derivados de indol e composição farmacêutica

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15
BR1100080-5A BR1100080A (pt) 1990-10-15 1996-11-12 Compostos derivados de indol e composição farmacêutica

Publications (1)

Publication Number Publication Date
BR1100080A true BR1100080A (pt) 2000-06-06

Family

ID=24393510

Family Applications (2)

Application Number Title Priority Date Filing Date
BR919106978A BR9106978A (pt) 1990-10-15 1991-10-08 Derivados de indol
BR1100080-5A BR1100080A (pt) 1990-10-15 1996-11-12 Compostos derivados de indol e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR919106978A BR9106978A (pt) 1990-10-15 1991-10-08 Derivados de indol

Country Status (33)

Country Link
EP (1) EP0592438B1 (pt)
JP (2) JP2575272B2 (pt)
KR (1) KR0179053B1 (pt)
CN (1) CN1039322C (pt)
AT (1) ATE157361T1 (pt)
AU (1) AU651637B2 (pt)
BG (1) BG61975B1 (pt)
BR (2) BR9106978A (pt)
CA (1) CA2091562C (pt)
DE (3) DE10299004I2 (pt)
DK (1) DK0592438T5 (pt)
EG (1) EG20224A (pt)
ES (1) ES2104733T3 (pt)
FI (1) FI105812B (pt)
GR (1) GR3025087T3 (pt)
HU (2) HU225055B1 (pt)
IE (1) IE913555A1 (pt)
IL (3) IL115117A (pt)
LU (1) LU90902I2 (pt)
MX (1) MX9101606A (pt)
MY (1) MY111683A (pt)
NL (1) NL300070I2 (pt)
NO (3) NO305121B1 (pt)
NZ (2) NZ240217A (pt)
OA (1) OA09874A (pt)
PL (3) PL168919B1 (pt)
PT (1) PT99218B (pt)
RO (1) RO111767B1 (pt)
RU (1) RU2095360C1 (pt)
SG (1) SG54270A1 (pt)
WO (1) WO1992006973A1 (pt)
YU (1) YU48088B (pt)
ZA (1) ZA918156B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
BR9206810A (pt) * 1991-11-25 1995-10-31 Pfizer Derivados de indol
TW288010B (pt) * 1992-03-05 1996-10-11 Pfizer
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
NZ251047A (en) * 1992-04-10 1996-09-25 Pfizer Acylaminoindole derivatives and medicaments
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (pt) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
US5607960A (en) * 1993-04-22 1997-03-04 Pfizer Inc. Indole derivatives as 5-HT1-like agonists for use in migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
DE69413240T2 (de) * 1993-08-31 1999-02-04 Pfizer 5-arylindolderivate
CA2195850A1 (en) * 1994-08-03 1996-02-15 Guillaume Lebaut Substituted indoles
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
CA2213241C (en) * 1994-10-12 2001-07-10 Pfizer Research And Development Company, N.V./S.A. Indole derivative for the treatment of migraine
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
WO1996029075A1 (en) * 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
WO1999053956A1 (fr) * 1998-04-16 1999-10-28 Yamanouchi Pharmaceutical Co., Ltd. Remedes contre l'obesite
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US6515141B1 (en) * 1999-08-26 2003-02-04 Fujisawa Pharmaceutical Co., Ltd. Process for the preparation of indole derivatives or salts thereof
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
CA2455050C (en) 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
JP4312256B2 (ja) 2005-06-15 2009-08-12 ファイザー・リミテッド 寄生生物に対して使用する置換アリールピラゾール
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
WO2006079999A2 (en) * 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
IT1393700B1 (it) * 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011024039A1 (en) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthesis of novel 5-(2-(phenylsulfonyl)ethyl)-1h-indole derivatives
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
WO2017125351A1 (en) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
CN114793420A (zh) 2020-01-22 2022-07-26 抗菌技术生物技术研究与发展股份有限公司 用于治疗脊髓损伤和改善运动功能的依来曲普坦氢溴酸盐
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (pt) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
SG54270A1 (en) 1998-11-16
IL99701A0 (en) 1992-08-18
PT99218A (pt) 1992-09-30
BG97632A (bg) 1994-03-31
AU651637B2 (en) 1994-07-28
YU165391A (sh) 1994-01-20
CN1039322C (zh) 1998-07-29
ATE157361T1 (de) 1997-09-15
KR0179053B1 (ko) 1999-03-20
JP2575272B2 (ja) 1997-01-22
LU90902I2 (fr) 2002-06-26
NZ270675A (en) 1997-07-27
ZA918156B (en) 1993-04-14
HUT64326A (en) 1993-12-28
JPH05507288A (ja) 1993-10-21
CA2091562A1 (en) 1992-04-16
YU48088B (sh) 1997-01-08
NO931378D0 (no) 1993-04-14
NL300070I2 (nl) 2002-03-01
ES2104733T3 (es) 1997-10-16
DE10299004I2 (de) 2006-03-16
HU9301098D0 (en) 1993-07-28
NZ240217A (en) 1995-05-26
JPH093063A (ja) 1997-01-07
DE69127468D1 (de) 1997-10-02
PL170330B1 (pl) 1996-11-29
DK0592438T5 (da) 1999-12-06
BG61975B1 (bg) 1998-11-30
RO111767B1 (ro) 1997-01-30
DK0592438T3 (da) 1997-09-29
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
EP0592438A1 (en) 1994-04-20
IL115117A0 (en) 1995-12-08
NO305121B1 (no) 1999-04-06
DE69127468T2 (de) 1998-01-02
NO985607D0 (no) 1998-12-01
OA09874A (en) 1994-09-15
FI931667A (fi) 1993-04-14
EG20224A (en) 1997-12-31
NO2001019I1 (no) 2001-12-03
MX9101606A (es) 1992-06-05
JP2677777B2 (ja) 1997-11-17
FI105812B (fi) 2000-10-13
DE9190141U1 (pt) 1993-07-15
PL169987B1 (en) 1996-09-30
IL115117A (en) 1996-11-14
CA2091562C (en) 2001-03-27
MY111683A (en) 2000-11-30
NL300070I1 (nl) 2002-02-01
PL168919B1 (pl) 1996-05-31
CN1062529A (zh) 1992-07-08
RU2095360C1 (ru) 1997-11-10
AU8950491A (en) 1992-05-20
IE913555A1 (en) 1992-04-22
NO931378L (no) 1993-04-14
IL99701A (en) 1996-10-31
BR9106978A (pt) 1993-09-28
NO985607L (no) 1998-12-01
PT99218B (pt) 1999-04-30
HU225055B1 (en) 2006-05-29
EP0592438B1 (en) 1997-08-27
DE10299004I1 (de) 2002-05-08
WO1992006973A1 (en) 1992-04-30

Similar Documents

Publication Publication Date Title
BR1100080A (pt) Compostos derivados de indol e composição farmacêutica
NO960818D0 (no) 5-Arylindol-derivater
MY108909A (en) Indole derivatives

Legal Events

Date Code Title Description
MT Patent procedure suspended until requirement met - articles 230 and 231 of law 9279/96
FGAN Processing applications according to articles 230 and 231 of law 9.279/96: granting
NB Patent issued - articles 230 and 231 of law 9279/96